![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon give very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C. Final results of the 4WIDUC study.
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Øvrehus1, H. Krarup2 , I. Birkemose3, D. K. Holm4, B. Mössner1, P. B. Christensen1. 1Department of Infectious Diseases, Odense University Hospital, Denmark 2 Section of Molecular Diagnostics and Clinical Biochemistry, Aalborg University Hospital, Denmark, Drug Treatment Center, Odense Municipality, Denmark and 4Department of Clinical Immunology, Odense University Hospital, Denmark.
![0426171](../images/042617/042617-2/0426171.gif)
![0426172](../images/042617/042617-2/0426172.gif)
![0426173](../images/042617/042617-2/0426173.gif)
![0426174](../images/042617/042617-2/0426174.gif)
![0426175](../images/042617/042617-2/0426175.gif)
![0426176](../images/042617/042617-2/0426176.gif)
![0426177](../images/042617/042617-2/0426177.gif)
![0426178](../images/042617/042617-2/0426178.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|